Results 121 to 130 of about 2,891 (162)
Some of the next articles are maybe not open access.
Expert Opinion on Pharmacotherapy
Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in the challenging landscape of relapsed/refractory multiple myeloma (RRMM).This article provides a review of selinexor, with a focus on available clinical studies involving MM patients and its safety profile.
Francesco Mendicino +2 more
exaly +3 more sources
Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in the challenging landscape of relapsed/refractory multiple myeloma (RRMM).This article provides a review of selinexor, with a focus on available clinical studies involving MM patients and its safety profile.
Francesco Mendicino +2 more
exaly +3 more sources
Selinexor in patients with advanced and recurrent endometrial cancer
Current Problems in Cancer, 2023Selinexor is an oral inhibitor of the nuclear export protein called Exportin 1 (XPO1) with demonstrated antitumor activity in hematological and solid tumors. Selinexor, blocking XPO1, induces nuclear localization of tumor suppressor proteins (including p53, p73, BRCA1, and pRB), leading to the selective induction of apoptosis, and inhibition of DNA ...
Bradley Monk +2 more
exaly +3 more sources
Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +1 more source
Selinexor for the treatment of multiple myeloma
Expert Opinion on Pharmacotherapy, 2020Introduction: Despite unprecedented advances in the treatment of multiple myeloma (MM), almost all patients develop a disease that is resistant to the five most commonly used and active anti-MM agents. The prognosis for this patient population is particularly poor resulting in an unmet need for additional therapeutic options.
Klaus, Podar +4 more
openaire +2 more sources
Selinexor: First Global Approval
Drugs, 2019Selinexor (XPOVIO™) is a first-in-class, oral, small molecule Exportin-1 (XPO1) inhibitor that is being developed by Karyopharm Therapeutics for the treatment of cancer. Selinexor (in combination with dexamethasone) received accelerated approval in the USA in July 2019 for the treatment of adult patients with relapsed or refractory multiple myeloma ...
openaire +2 more sources
Upregulation of BCMA expression by selinexor
BloodAbstract Introduction Selinexor is a first-in-class, selective inhibitor of nuclear export that targets exportin 1 (XPO1), a key nuclear export protein involved in the transport of tumor suppressor proteins and oncogenic factors from the nucleus to the cytoplasm.
Christina Verbruggen +13 more
openaire +1 more source
Selinexor dose optimization: A retrospective analysis.
JCO Oncology Practice296 Background: Several oral oncolytics are approved at doses that require early and frequent intervention to manage associated toxicities. This retrospective analysis investigated efficacy and safety outcomes of patients initiated on lower doses (≤ 80 mg) of selinexor compared to those who ...
Rachel Hauf +8 more
openaire +1 more source